CureVac

About CureVac

CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has its headquarters in Tübingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium, Switzerland and the U.S. Further information can be found at www.curevac.com.

Website	http://curevac.com
Employees	501-1,000 employees View all CureVac employees
Industry	Biotechnology
Phone number	+49707198830
Headquarter	Friedrich-Miescher-Str. 15, Tübingen, Baden-Württemberg 72076, DE
Founded	2000
Keywords	Oncology, Research And Development, Manufacturing, Oncology, Mrna Therapeutics, Cancer Therapies, Prophylactic Vaccines, Molecular Therapies, Manufacturing, Research And Development, Mrna Therapeutics, Prophylactic Vaccines